Antiviral Treatment in Older Chinese Patient with SARS-CoV-2 and Influenza A Virus Co-Infection: A Case Series

Abstract

Wenjuan Yang,1,2 Bing Han,1 Bei Zheng,1 Ying Li,1 Tiefei Yao,3 Mei Han,3 Gonghua Li,1 Meiling Zhang1 1Department of Pharmacy, Tongde Hospital of ZheJiang Province, Hangzhou, Zhejiang, People’s Republic of China; 2Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, Zhejiang, People’s Republic of China; 3Department of Geriatric Medicine, Tongde Hospital of ZheJiang Province, Hangzhou, Zhejiang, People’s Republic of ChinaCorrespondence: Gonghua Li; Meiling Zhang, Department of Pharmacy, Tongde Hospital of ZheJiang Province, Hangzhou, Zhejiang, People’s Republic of China, Tel [phone], Email [email protected]; [email protected]: Coronavirus disease 2019 (COVID-19) emergence in late 2019, and wide spread quickly in the world. In China, the COVID-19 epidemic situation entered a low level now. With the arrival of flu season, the number of patients with respiratory symptoms is increasing. We reported three cases of patients who co-infected with SARS-CoV-2 and influenza A virus (IAV), and they were all treated with nirmatrelvir-ritonavir (NMV/r) and baloxavir marboxil. Due to the overlapping clinical features between the two diseases, it is important to identified them and gave the antiviral therapy timely.Keywords: COVID-19, influenza, co-infection, baloxavir marboxil, nirmatrelvir-ritonavir

Keywords

• covid-19
• influenza
• co-infection
• baloxavir marboxil
• nirmatrelvir-ritonavir